ATE482271T1 - Lna-oligonukleotide und krebsbehandlung - Google Patents

Lna-oligonukleotide und krebsbehandlung

Info

Publication number: ATE482271T1
Authority: AT; Austria
Prior art keywords: lna; beta; oligonucleotides; inhibition; lna oligonucleotides
Prior art date: 2004-11-09

Application number

AT05800759T

Other languages

English (en)

Inventor

Lene Sonderbye Kjfrulff

Marlene Asklund

Majken Westergaard

Christoph Rosenbohm

Margit Wissenbach

Bo Hansen

Original Assignee

Santaris Pharma As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-11-09

Filing date

2005-11-09

Publication date

2010-10-15

2005-11-09 Application filed by Santaris Pharma As filed Critical Santaris Pharma As

2005-11-09 Priority claimed from PCT/DK2005/000719 external-priority patent/WO2006050732A2/en

2010-10-15 Application granted granted Critical

2010-10-15 Publication of ATE482271T1 publication Critical patent/ATE482271T1/de

Links

108091034117 Oligonucleotide Proteins 0.000 title abstract 5
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract 5
206010028980 Neoplasm Diseases 0.000 title abstract 3
201000011510 cancer Diseases 0.000 title abstract 2
230000005764 inhibitory process Effects 0.000 abstract 3
102000000763 Survivin Human genes 0.000 abstract 2
108010002687 Survivin Proteins 0.000 abstract 2
230000006907 apoptotic process Effects 0.000 abstract 2
108020004999 messenger RNA Proteins 0.000 abstract 2
229930012538 Paclitaxel Natural products 0.000 abstract 1
230000000692 anti-sense effect Effects 0.000 abstract 1
230000002222 downregulating effect Effects 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
230000006698 induction Effects 0.000 abstract 1
229960001592 paclitaxel Drugs 0.000 abstract 1
230000003389 potentiating effect Effects 0.000 abstract 1
230000035755 proliferation Effects 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
230000008685 targeting Effects 0.000 abstract 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT05800759T 2004-11-09 2005-11-09 Lna-oligonukleotide und krebsbehandlung ATE482271T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US62656104P	2004-11-09	2004-11-09
DKPA200401728		2004-11-09
PCT/DK2005/000719 WO2006050732A2 (en)	2004-11-09	2005-11-09	Lna oligonucleotides and the treatment of cancer

Publications (1)

Publication Number	Publication Date
ATE482271T1 true ATE482271T1 (de)	2010-10-15

Family

ID=38965697

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05800759T ATE482271T1 (de)	2004-11-09	2005-11-09	Lna-oligonukleotide und krebsbehandlung

Country Status (6)

Country	Link
CN (1)	CN101065485B (de)
AT (1)	ATE482271T1 (de)
DE (1)	DE602005023772D1 (de)
DK (1)	DK1824975T3 (de)
ES (1)	ES2353638T3 (de)
ZA (1)	ZA200704254B (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20110091796A (ko) *	2008-12-04	2011-08-12	오피케이오 큐알엔에이, 엘엘씨	종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE356824T1 (de) *	1999-05-04	2007-04-15	Santaris Pharma As	L-ribo-lna analoge
AU2003229930A1 (en) *	2002-04-24	2003-11-10	University Of Bern	A role for survivin in apoptosis of myeloid cells
MXPA05008319A (es) *	2003-02-10	2006-02-28	Santaris Pharma As	Compuestos oligomericos para la modulacion de la expresion de survivina.

2005
- 2005-11-09 AT AT05800759T patent/ATE482271T1/de not_active IP Right Cessation
- 2005-11-09 DK DK05800759.2T patent/DK1824975T3/da active
- 2005-11-09 CN CN2005800409084A patent/CN101065485B/zh not_active Expired - Fee Related
- 2005-11-09 ZA ZA200704254A patent/ZA200704254B/xx unknown
- 2005-11-09 DE DE602005023772T patent/DE602005023772D1/de not_active Expired - Lifetime
- 2005-11-09 ES ES05800759T patent/ES2353638T3/es not_active Expired - Lifetime

Also Published As

Publication number	Publication date
DK1824975T3 (da)	2011-06-06
CN101065485B (zh)	2011-12-07
ES2353638T9 (es)	2011-06-16
ZA200704254B (en)	2009-09-30
ES2353638T3 (es)	2011-03-03
CN101065485A (zh)	2007-10-31
DE602005023772D1 (de)	2010-11-04

Similar Documents

Publication	Publication Date	Title
WO2006050732A3 (en)	2007-05-31	Lna oligonucleotides and the treatment of cancer
Han et al.	2013	Silencing of the STAT3 signaling pathway reverses the inherent and induced chemoresistance of human ovarian cancer cells
Tanigawa et al.	2008	Stabilization of p53 is involved in quercetin-induced cell cycle arrest and apoptosis in HepG2 cells
MX2007013632A (es)	2008-01-24	Procedimientos para preparar derivados de bencil-benceno sustituidos con glucopiranosilo y sus productos intermedios.
Li et al.	2015	Synthesis and biological evaluation of nitric oxide-releasing hybrids from gemcitabine and phenylsulfonyl furoxans as anti-tumor agents
WO2004044160A3 (en)	2005-04-28	Muc1 interference rna compositions and methods derived therefrom
Hao et al.	2020	Design, synthesis and biological evaluation of novel carbohydrate-based sulfonamide derivatives as antitumor agents
Xue et al.	2012	Inhibitory effect of riccardin D on growth of human non-small cell lung cancer: in vitro and in vivo studies
Cai et al.	2021	Design, synthesis, and anticancer evaluation of novel andrographolide derivatives bearing an α, β-unsaturated ketone moiety
Wang et al.	2012	The role of protein arginine-methyltransferase 1 in gliomagenesis
Wang et al.	2023	Design, synthesis, and biological evaluation of a series of benzofuran [3, 2-d] pyrimidine-4 (3H)-one derivatives containing thiosemicarbazone analogs as novel PARP-1 inhibitors
Zhang et al.	2020	Licochalcone A restrains microphthalmia‐associated transcription factor expression and growth by activating autophagy in melanoma cells via miR‐142‐3p/Rheb/mTOR pathway
Oh et al.	2017	In silico investigation of lavandulyl flavonoids for the development of potent fatty acid synthase-inhibitory prototypes
Kim et al.	2010	Anti-tumor effects by a synthetic chalcone compound is mediated by c-Myc-mediated reactive oxygen species production
Nyein et al.	2018	Synthesis and anti-glioblastoma effects of artemisinin-isothiocyanate derivatives
ATE482271T1 (de)	2010-10-15	Lna-oligonukleotide und krebsbehandlung
Moorkoth	2015	Synthesis and anti-cancer activity of novel thiazolidinone analogs of 6-aminoflavone
Kaskiw et al.	2008	Synthesis and cytotoxic activity of diosgenyl saponin analogues
Huang et al.	2012	Glycosylated diazeniumdiolate-based oleanolic acid derivatives: synthesis, in vitro and in vivo biological evaluation as anti-human hepatocellular carcinoma agents
Madhu et al.	2017	Synthesis of pyrazole-substituted chromene analogues with selective anti-leukemic activity
Holmqvist et al.	2013	Synthesis and biology of oligoethylene glycol linked naphthoxylosides
Wu et al.	2018	Discovery of novel negletein derivatives as potent anticancer agents for acute myeloid leukemia
Ruan et al.	2022	Dual diomarkers triggered prodrugs for precise treatment of melanoma: Design, synthesis and activities
Sakuda et al.	2006	Synthesis of galloyl-substituted procyanidin B4 series, and their DPPH radical scavenging activity and DNA polymerase inhibitory activity
Bilajac et al.	2023	Analysis of Antitumor Potential of Xanthene Compounds in Lymphoma Cells

Legal Events

Date	Code	Title	Description
2011-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties